Neurosonics, which has successfully completed a series of animal experiments, will begin human experiments this summer
Avi Blizovsky
Direct link to this page: http://wwwhayadan.org.il/neuromatix.html
The Israeli medical device company Neurosonics has completed a fundraising round of approximately 1.4 million dollars. The fundraising round was led by the Ofer Hi-Tech Group and the venture capital funds Yozama and Peregrine, and was attended by other Israeli and American investors, including a number of key figures in the field of life sciences in the US. Top Notch Capital, an investment bank specializing in life sciences, managed the fundraising round.
The Neurosonics company was established in 2002 at the Incentiv incubator in Ariel by Dr. Natan Sela, and develops non-invasive technology to protect against emboli that form during open heart surgery and catheterization. The first product developed by Neurosonics is intended for use in open heart surgery and the market potential for this product is estimated at about one billion dollars per year. In the western world, about 1.5 million open heart surgeries are performed every year. Neurosonics is managed by Dr. Natan Sela, a graduate of Talpiot and a doctor of physics.
"The rate of brain damage following open heart surgery is very high and unacceptable, especially when it comes to such a common procedure," says Dr. Natan Sela, and adds: "On average, about 3% of open heart surgery patients suffer from a stroke, and another tens of percent suffer from cognitive damage in different degrees. In a conservative estimate, these problems cost the US economy alone between 2.5-4 billion dollars each year."
Neurosonics employs 6 people in the development center located in Or Yehuda. Last year, the company successfully completed the phase of the series of experiments on animals and intends to start this summer with experiments on humans that will be carried out in Europe.
https://www.hayadan.org.il/BuildaGate4/general2/data_card.php?Cat=~~~116037716~~~221&SiteName=hayadan
